Treos Bio’s PolyPEPI™ Precision Cancer Vaccine Metastatic Colorectal Cancer

Please feel free to read, share your thoughts, your stories and connect with others!
Schallen
Posts: 7
Joined: Sun Mar 18, 2018 9:26 pm
Facebook Username: Schallen

Treos Bio’s PolyPEPI™ Precision Cancer Vaccine Metastatic Colorectal Cancer

Postby Schallen » Wed May 16, 2018 7:45 pm

SAN FRANCISCO and LONDON, May 14, 2018 (GLOBE NEWSWIRE) -- Treos Bio Limited, an immuno-oncology company developing next-generation, off-the-shelf precision cancer vaccines coupled with companion diagnostics, today said investigators dosed the first patient in its Phase 1 trial of PolyPEPI™ 1018, the company’s investigational precision cancer vaccine for patients with metastatic colorectal cancer (mCRC).

The phase 1 trial is investigating the safety, tolerability, and immunogenicity of the PolyPEPI 1018 CRC Vaccine as an add-on treatment to the standard-of-care maintenance therapy in patients with metastatic colorectal cancer. Vaccine induced T cell immune responses and tumor-infiltrating lymphocytes will be determined by bioassays and the correlation with the predicted T cell immune responses will also be assessed. Mayo Clinic is serving as the only U.S. site for the study.

Despite advances made in therapies to treat colorectal cancer, metastatic colorectal cancer continues to be poorly addressed by available therapies and is today the second leading cause of cancer death in the United States.

“While Treos has made great progress and we are proud to achieve this milestone of dosing the first patient in this first-in-man study of our precision cancer vaccine, we feel the urgency of patients with metastatic colorectal cancer in search of better therapeutic options,” said Dr. Menghis Bairu, Executive Chairman of Treos.

A total of 10 adult patients between the ages of 18 and 75, who have experienced either a partial response or stable disease during first‑line treatment with a systemic chemotherapy regimen and one biological therapy regimen, are being enrolled in the study. Patients interested in participating in the study can find a fuller description of the enrollment criteria on the ClinicalTrials.gov website [ClinicalTrials.gov Identifier: NCT03391232].

“Treos has long worked to understand how to stimulate the human immune system to destroy tumor cells without attacking healthy cells,” said Franco Lori, M.D, Ph.D., Chief Medical Officer of Treos Bio. “As we treat the first patient in this study of our off-the-shelf, precision cancer vaccine, it moves us one step closer to addressing an unmet need of patients and combatting this deadly disease.”

About PolyPEPI™ 1018 CRC Vaccine
The vaccine contains six synthetic peptides that are precisely selected to induce T cell responses against 12 epitopes from seven cancer testis antigens (CTAs) most frequently expressed in colorectal cancers. These peptides are optimized with the PEPI biomarker to induce robust and lasting CRC specific T cell responses.


https://globenewswire.com/news-release/ ... ancer.html

NHMike
Posts: 1232
Joined: Fri Jul 21, 2017 3:43 am

Re: Treos Bio’s PolyPEPI™ Precision Cancer Vaccine Metastatic Colorectal Cancer

Postby NHMike » Thu May 17, 2018 7:54 am

That's very exciting. Is this work a follow-on to NCI's work?
6/23/17: ER rectal bleeding; Colonoscopy
7/13: Stage 3B rectal. T3N1bM0. 5.2 x 4.5 x 4.3 cm. Lymphs: 6 x 4 mm, 8 x 6, 5 x 5
7/31-9/8: Xeloda 3,400 mg/day+radiation
7/5: CEA 2.7; 8/16: 1.9; 9/8: 1.8; 11/30: 0.6; 12/20 1.4; 1/10 1.8; 1/31 2.2; 2/28 2.6; 4/10 2.8
MSS, KRAS G12D
10/6: 2.7 x 2.2 x 1.6 cm (-90%). Lymphs: 3 x 3 mm (-62.5%), 4 x 3 (-75%), 5 x 3 (-40%). 5.1 CM from AV
10/30: LAR, Temp Ileostomy, Path Complete Response
12/20: Started CapeOx

User avatar
juliej
Posts: 2814
Joined: Thu Aug 05, 2010 12:59 pm

Re: Treos Bio’s PolyPEPI™ Precision Cancer Vaccine Metastatic Colorectal Cancer

Postby juliej » Mon May 21, 2018 6:05 pm

Really interesting vaccine. The trial uses the vaccine (which induces an optimized immune response) as an add-on treatment to regular chemo. Sounds promising!

They are recruiting patients at the Mayo Clinic in Rochester, Minnesota. Here's the trial info:

https://clinicaltrials.gov/ct2/show/NCT03391232
Stage IV, liver/lung mets 8/4/2010
Xelox+Avastin 8/18/10 to 10/21/11
LAR, liver resec, HAI pump 11/11
Double lung surgery + ileo reversal 2/12
Adjuvant Xeloda 3-9/12
VATS rt. lung 12/21/12 - benign granuloma!
NED 3/17/12 to 3/19/2018, CEA<1

NHMike
Posts: 1232
Joined: Fri Jul 21, 2017 3:43 am

Re: Treos Bio’s PolyPEPI™ Precision Cancer Vaccine Metastatic Colorectal Cancer

Postby NHMike » Mon May 21, 2018 6:58 pm

I had a look around the web (including the trial) for details and I couldn't find any. It references the most common CRCs and I have some knowledge of the first two most common but it would be nice if they listed out the genetic mutations covered by the vaccine. I am pretty sure that I know what they did but it would be nice to see it in a paper.
6/23/17: ER rectal bleeding; Colonoscopy
7/13: Stage 3B rectal. T3N1bM0. 5.2 x 4.5 x 4.3 cm. Lymphs: 6 x 4 mm, 8 x 6, 5 x 5
7/31-9/8: Xeloda 3,400 mg/day+radiation
7/5: CEA 2.7; 8/16: 1.9; 9/8: 1.8; 11/30: 0.6; 12/20 1.4; 1/10 1.8; 1/31 2.2; 2/28 2.6; 4/10 2.8
MSS, KRAS G12D
10/6: 2.7 x 2.2 x 1.6 cm (-90%). Lymphs: 3 x 3 mm (-62.5%), 4 x 3 (-75%), 5 x 3 (-40%). 5.1 CM from AV
10/30: LAR, Temp Ileostomy, Path Complete Response
12/20: Started CapeOx


Return to “Colon Talk - Colon cancer (colorectal cancer) support forum”



Who is online

Users browsing this forum: Google Feedfetcher, Yahoo [Bot] and 29 guests